IBDEI0AH ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13287,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,13287,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,13287,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,13288,0)
 ;;=C82.69^^43^624^52
 ;;^UTILITY(U,$J,358.3,13288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13288,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13288,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,13288,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,13289,0)
 ;;=C82.60^^43^624^53
 ;;^UTILITY(U,$J,358.3,13289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13289,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,13289,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,13289,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,13290,0)
 ;;=D56.2^^43^624^54
 ;;^UTILITY(U,$J,358.3,13290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13290,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,13290,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,13290,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,13291,0)
 ;;=D75.9^^43^624^55
 ;;^UTILITY(U,$J,358.3,13291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13291,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,13291,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,13291,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,13292,0)
 ;;=D59.0^^43^624^58
 ;;^UTILITY(U,$J,358.3,13292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13292,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,13292,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,13292,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,13293,0)
 ;;=D59.2^^43^624^59
 ;;^UTILITY(U,$J,358.3,13293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13293,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,13293,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,13293,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,13294,0)
 ;;=R59.9^^43^624^62
 ;;^UTILITY(U,$J,358.3,13294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13294,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,13294,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,13294,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,13295,0)
 ;;=D47.3^^43^624^63
 ;;^UTILITY(U,$J,358.3,13295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13295,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,13295,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,13295,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,13296,0)
 ;;=C82.09^^43^624^64
 ;;^UTILITY(U,$J,358.3,13296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13296,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13296,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,13296,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,13297,0)
 ;;=C82.00^^43^624^65
 ;;^UTILITY(U,$J,358.3,13297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13297,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,13297,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,13297,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,13298,0)
 ;;=C82.19^^43^624^66
 ;;^UTILITY(U,$J,358.3,13298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13298,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13298,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,13298,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,13299,0)
 ;;=C82.10^^43^624^67
 ;;^UTILITY(U,$J,358.3,13299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13299,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,13299,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,13299,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,13300,0)
 ;;=C82.29^^43^624^68
 ;;^UTILITY(U,$J,358.3,13300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13300,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13300,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,13300,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,13301,0)
 ;;=C82.20^^43^624^69
 ;;^UTILITY(U,$J,358.3,13301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13301,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,13301,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,13301,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,13302,0)
 ;;=C82.39^^43^624^70
 ;;^UTILITY(U,$J,358.3,13302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13302,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13302,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,13302,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,13303,0)
 ;;=C82.30^^43^624^71
 ;;^UTILITY(U,$J,358.3,13303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13303,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,13303,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,13303,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,13304,0)
 ;;=C82.49^^43^624^72
 ;;^UTILITY(U,$J,358.3,13304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13304,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13304,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,13304,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,13305,0)
 ;;=C82.40^^43^624^73
 ;;^UTILITY(U,$J,358.3,13305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13305,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,13305,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,13305,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,13306,0)
 ;;=C82.99^^43^624^74
 ;;^UTILITY(U,$J,358.3,13306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13306,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13306,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,13306,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,13307,0)
 ;;=C82.90^^43^624^75
 ;;^UTILITY(U,$J,358.3,13307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13307,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,13307,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,13307,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,13308,0)
 ;;=R59.1^^43^624^60
 ;;^UTILITY(U,$J,358.3,13308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13308,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,13308,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,13308,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,13309,0)
 ;;=C91.40^^43^624^79
 ;;^UTILITY(U,$J,358.3,13309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13309,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,13309,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,13309,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,13310,0)
 ;;=C91.42^^43^624^77
 ;;^UTILITY(U,$J,358.3,13310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13310,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,13310,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,13310,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,13311,0)
 ;;=C91.41^^43^624^78
 ;;^UTILITY(U,$J,358.3,13311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13311,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,13311,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,13311,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,13312,0)
 ;;=D57.01^^43^624^80
 ;;^UTILITY(U,$J,358.3,13312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13312,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,13312,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,13312,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,13313,0)
 ;;=D57.00^^43^624^81
 ;;^UTILITY(U,$J,358.3,13313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13313,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,13313,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,13313,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,13314,0)
 ;;=D57.02^^43^624^82
 ;;^UTILITY(U,$J,358.3,13314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13314,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,13314,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,13314,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,13315,0)
 ;;=D68.32^^43^624^84
 ;;^UTILITY(U,$J,358.3,13315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13315,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,13315,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,13315,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,13316,0)
 ;;=C22.2^^43^624^85
 ;;^UTILITY(U,$J,358.3,13316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13316,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,13316,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,13316,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,13317,0)
 ;;=D58.9^^43^624^87
 ;;^UTILITY(U,$J,358.3,13317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13317,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,13317,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,13317,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,13318,0)
 ;;=C81.99^^43^624^88
 ;;^UTILITY(U,$J,358.3,13318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13318,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,13318,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,13318,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,13319,0)
 ;;=C81.90^^43^624^89
 ;;^UTILITY(U,$J,358.3,13319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13319,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,13319,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,13319,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,13320,0)
 ;;=D89.2^^43^624^90
 ;;^UTILITY(U,$J,358.3,13320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13320,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,13320,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,13320,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,13321,0)
 ;;=D05.12^^43^624^91
 ;;^UTILITY(U,$J,358.3,13321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13321,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,13321,1,4,0)
 ;;=4^D05.12
